06.19.06
Jeffrey J. Stoddard, M.D. has been named vice president, medical and scientific affairs, risk management and postmarketing programs at Covance. In this capacity, Dr. Stoddard will lead Covance's risk management and postmarketing business and have responsibility for providing scientific and technical leadership in these important areas.
"Dr. Stoddard's broad background of medical practice, his close links with leading academic institutions and government agencies, and his work on vaccines in vulnerable populations make him the ideal person to meet the industry's growing need for leadership in risk management and benefit characterization," said Dr. Larry Meinert, Covance's senior vice president, medical and scientific affairs. "Working within a scientific and operational community that spans the drug development continuum from early, to late-stage and commercialization, Dr. Stoddard and his team will be able to help Covance clients build risk management into the core of their development processes."
Dr. Stoddard will lead the Covance Risk Management Expert Panel, an internal team of scientific experts in preclinical and clinical research, regulatory affairs, drug safety, epidemiology and commercialization. This panel provides clients with comprehensive risk management consulting from preclinical testing through commercialization.
Prior to joining Covance, Dr. Stoddard was senior director, medical affairs at MedImmune and also a physician researcher for the Center for Studying Health System Change.
"Dr. Stoddard's broad background of medical practice, his close links with leading academic institutions and government agencies, and his work on vaccines in vulnerable populations make him the ideal person to meet the industry's growing need for leadership in risk management and benefit characterization," said Dr. Larry Meinert, Covance's senior vice president, medical and scientific affairs. "Working within a scientific and operational community that spans the drug development continuum from early, to late-stage and commercialization, Dr. Stoddard and his team will be able to help Covance clients build risk management into the core of their development processes."
Dr. Stoddard will lead the Covance Risk Management Expert Panel, an internal team of scientific experts in preclinical and clinical research, regulatory affairs, drug safety, epidemiology and commercialization. This panel provides clients with comprehensive risk management consulting from preclinical testing through commercialization.
Prior to joining Covance, Dr. Stoddard was senior director, medical affairs at MedImmune and also a physician researcher for the Center for Studying Health System Change.